

# Appendixes

# Appendix A.— Health Program Advisory Committee and Acknowledgments

---

## HEALTH PROGRAM ADVISORY COMMITTEE

Sidney S. Lee, *Chair*  
Michael Reese Hospital and Medical Center

Stuart H. Altman\*  
Florence Heller School  
Brandeis University

Carroll L. Estes  
Department of Social and Behavioral Sciences  
School of Nursing  
University of California, San Francisco

Rashi Fein  
Department of Social Medicine and Health Policy  
Harvard Medical School

Melvin A. Glasser  
Health Security Action Council-  
Committee for National Health Insurance

Patricia King  
Georgetown Law Center

Joyce C. Lashof  
School of Public Health  
University of California, Berkeley

Margaret Mahoney  
The Commonwealth Fund

Frederick Mosteller  
Department of Health Policy and Management  
School of Public Health  
Harvard University

Mitchell Rabkin\*  
Beth Israel Hospital  
Boston, Mass.

Dorothy P. Rice  
Department of Social and Behavioral Sciences  
School of Nursing  
University of California, San Francisco

Richard K. Riegelman  
George Washington University  
School of Medicine

Walter L. Robb  
Medical Systems Operations  
General Electric  
Milwaukee, Wis.

Frederick C. Robbins  
Institute of Medicine

Rosemary Stevens  
Department of History and Sociology Science  
University of Pennsylvania

---

● Until April 1983.

## ACKNOWLEDGMENTS

The development of this case study was greatly aided by the advice and review of a number of people in addition to the Advisory Panel for the assessment of *Medical Technology* and *Costs of the Medicare care Program* and the Health Program Advisory Panel. The case study director and OTA staff would like to express their appreciation especially to the following individuals:

Cheryl Anderson, Advocacy International, Ltd.  
 Jack M. Anthony, Travenol Laboratories, Inc.  
 Thomas Asher, Immunogenetics, Inc.  
 Robert Berenson, Washington, D.C.  
 Eugene Berkman, Tufts New England Medical Center  
 Gary F. Brown, Seattle, Wash.  
 Meredith F. Buco, Blue Cross/Blue Shield Association  
 Maria Charest, Arthur D. Little, Inc., Cambridge, Mass.  
 Arthur A. Ciarkowski, Food and Drug Administration  
 Vincent Ciuryla, E. I. du Pont de Nemours & Co., Inc.  
 P. P. Clymer, Office of Technology Assessment  
 Robert M. Collins, Cobe Laboratories, Inc.  
 Dennis Cotter, Office of Health Technology Assessment  
 W. Palmer Dearing, Blue Cross/Blue Shield Association  
 Vincent T. DeVita, Jr., National Cancer Institute  
 Allen J. Douma, American Medical Association  
 Frances Edmondson, Travenol Laboratories, Inc.  
 Lenny Friedman, American Red Cross  
 W. Bradford Gary, Travenol Laboratories, Inc.  
 Murray Goldstein, National Institute of Neurological and Communicative Disorders and Stroke  
 Max I. Hamburger, State University of New York at Stony Brook

Steven Heyse, National Institute of Arthritis, Diabetes, and Digestive and Kidney Disease  
 Terry Hollis, Blue Cross/Blue Shield of Massachusetts  
 Douglas W. Huestis, University of Arizona  
 John Verrier Jones, Dalhousie University, Nova Scotia, Canada  
 Richard Landfield, Goodell, Landfield, Becker, Green & Martingale, Washington, D.C.  
 Claude Lenfant, National Heart, Lung, and Blood Institute  
 Joshua Levy, Immunogenetics, Inc.  
 L. M. Magner, E. I. du Pont de Nemours & Co., Inc.  
 Guy M. McKhann, Johns Hopkins Hospital  
 Donald Myers, RMR Health and Hospital Consultants, Inc.  
 Terri Louise Nally, American Chemical Society  
 Nan Newell, Office of Technology Assessment  
 Robert K. Oldham, National Cancer Institute  
 Robert W. Reilly, American Blood Resources Association  
 J. Gerald Sandier, American Red Cross  
 Phillips L. Scoville, Scoville Associates, Greenville, S. C.  
 Ira D. Singer, Project Hope  
 Glenda Sweeney, American Red Cross  
 Garry Vibert, Parker-Hannifin Corp.  
 Donald Young, Health Care Financing Administration